Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27582477 | 0.99 | CYP19A1 (0.52) | CYP19A1HTR2CHTR1ASIGMAR1ACHE | |
| SCHEMBL8536795 | 0.96 | CYP19A1 (0.54) | CYP19A1HTR2CHTR1ASIGMAR1ACHE | |
| SCHEMBL7672871 | 0.90 | CYP19A1 (0.57) | CYP19A1HTR2CHTR1ASIGMAR1ACHE | |
| SCHEMBL7163249 | 0.84 | HDAC1 (0.50) | CYP19A1HTR2CALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL11156946 | 0.83 | CYP19A1 (0.48) | CYP19A1HTR2CHTR1ASIGMAR1ACHE | |
| SCHEMBL27582486 | 0.82 | KDM4E (0.49) | CYP19A1HTR2CALDH1A1CYP26A1 | |
| SCHEMBL8534917 | 0.81 | ACHE (0.51) | CYP19A1HTR2CHTR1ASIGMAR1ACHE | |
| SCHEMBL31296097 | 0.81 | CYP19A1 (0.57) | CYP19A1HTR2CHTR1ASIGMAR1ACHE | |
| SCHEMBL6272342 | 0.81 | CYP19A1 (0.57) | CYP19A1HTR2CHTR1ASIGMAR1ACHE | |
| SCHEMBL28776115 | 0.81 | HTR2C (0.55) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100340545-C | Tetralone derivatives as antitumor agents | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | CN | claimed |
| CN-1478072-A | Tetralone derivatives as antitumor agents | - | 2004-02-25 | — | — | CN | claimed |
| CN-100340545-C | Tetralone derivatives as antitumor agents | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | CN | disclosed |
| CN-1478072-A | Tetralone derivatives as antitumor agents | - | 2004-02-25 | — | — | CN | disclosed |
| EP-1349830-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6531472-B2 | Has histone deacetylase (HDAC) inhibitory activity which is useful in cancer treatment | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2002046144-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| US-20020065282-A1 | Tetralone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | US | disclosed |
| US-5847159-A | 1- ω-(3,4-dihydro-2-naphthalenyl)alkyl!-cyclic amine derivatives, process for preparing the same, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| EP-0825180-A1 | 1-OMEGA-(3,4-DIHYDRO-2-NAPHTHALENYL)ALKYL] CYCLIC AMINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065282-A1 | Tetralone derivatives | HDAC1, HDAC5, HDAC3 | CYP19A1 717/4885HTR2C 2670/4885HTR1A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.